Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Want to see VVOS full AI Analyst Report?
Earnings Data
Report Date
May 18, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.45Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: operationally the company demonstrated meaningful progress from its strategic pivot (16% revenue growth, diagnostic and treatment revenue ramp, in-network payer wins, and strong patient demand), and it is building a scalable affiliation model with attractive per-team economics. However, these achievements are offset by sizable near-term financial challenges — a large FY2025 net loss ($21.2M), sharply higher operating expenses, meaningful cash burn, a thin year-end cash balance ($2M), and increased liabilities including short-term debt due in 2026. Management has raised post-period capital and expects revenue and provider staffing to improve in 2026, but continued execution and additional financing will be required to fully realize the upside. Overall, positives and negatives are roughly balanced.Company Guidance
Full-Year Revenue and Gross Profit Growth
Revenue increased by $2.4 million or 16% year-over-year for FY2025. Gross profit rose to $10.5 million (a 17% increase) while gross margin remained steady at 60% year-over-year.
Strong Diagnostic and Treatment Revenue from SCN
Sleep testing (diagnostic) revenue was approximately $6.0 million in 2025, driven by Sleep Center of Nevada (SCN), representing an increase of about $4.8 million versus 2024. Treatment revenue from SCN locations contributed approximately $2.2 million. Combined, these new-model diagnostic and treatment revenues represent the core growth engine for the company.
In-Network Insurance Access and High Patient Demand
SCN received in-network status with a number of commercial payers and participating status with Medicare, improving patient access. At year-end 2025 the two onboarded SCN locations were fully booked through April 2026 and management reported processing fewer than 40% of patients seeking appointments, indicating strong unmet demand.
New MSO/DSO Affiliation Model and SO Teams with High Potential Economics
Vivos deployed approximately 1.5 Sleep Optimization (SO) teams across two SCN locations and expects more in 2026. Management estimates each SO team could generate collections well in excess of $500,000 per month (net of adjustments) with contribution margins above 50%. Reported revenue per case in Nevada averages just under $5,000 with contribution margins >50%. The affiliation model is presented as capital efficient (<$1M typical outlay) compared with acquisitions.
Post-Period Capital Raises Bolstering Liquidity
After year-end, the company raised $4.6 million gross proceeds from a warrant inducement (Jan 16, 2026) and completed a $2.25 million private placement (Apr 7, 2026) with an existing investor to strengthen post-year-end stockholders' equity.
Operational and Clinical Momentum
Management reported growing clinical endorsement from medical sleep specialists, expanded facilities and staffing at SCN in response to patient demand, ongoing R&D progress with expected case studies/publications, and inbound interest from large specialty medical groups seeking affiliations.
VVOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VVOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 15, 2026 | $1.47 | $1.09 | -25.85% |
Nov 19, 2025 | $2.36 | $2.12 | -10.17% |
Aug 19, 2025 | $4.27 | $4.13 | -3.28% |
May 15, 2025 | $3.06 | $2.54 | -16.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vivos Therapeutics (VVOS) report earnings?
Vivos Therapeutics (VVOS) is schdueled to report earning on May 18, 2026, After Close (Confirmed).
What is Vivos Therapeutics (VVOS) earnings time?
Vivos Therapeutics (VVOS) earnings time is at May 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VVOS EPS forecast?
Currently, no data Available